Hyperlipoproteinemia Type II clinical trials
The registry lists 249 studies for Hyperlipoproteinemia Type II across more than 10 countries. 56 are recruiting or about to start. 164 of them are mainly about Hyperlipoproteinemia Type II (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Homozygous Familial Hypercholesterolemia too: 295 studies, 64 open.
Get an email when these change. Save the Hyperlipoproteinemia Type II studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Merck Sharp & Dohme LLC (17) · Novartis Pharmaceuticals (9) · Organon and Co (9) · Amgen (6) · Laval University (6) · Kastle Therapeutics, LLC (6) · University of Pennsylvania (5) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (5)
What is being tested here
Drugs under test in Hyperlipoproteinemia Type II studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Inclisiran | 3 | 3 | 6 |
| QLC7401 | 3 | 2 | 3 |
| Lerodalcibep | 2 | 2 | 2 |
| Zodasiran | 1 | 1 | 2 |
| Omega-3 fatty acid | 1 | 1 | 2 |
| 2-(AMINOMETHYL)PHENOL | 1 | 0 | 1 |
| SYH2070 | 1 | 0 | 1 |
| SYH2053 | 1 | 1 | 1 |
| Evolocumab | 0 | 4 | 7 |
| Atorvastatin | 0 | 5 | 7 |
Drug classes tested here PCSK9 inhibitors 2 open · Statins 17
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Oct 2027QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Dec 2026Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH · Tang-Du Hospital
- Dec 2026Specified Drug-use Survey of Leqvio for s.c. Injection. · Novartis Pharmaceuticals
- Jan 2027Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) · Geisinger Clinic
- Feb 2027Penn Family Screening for Familial Hypercholesterolemia · Northwestern University
- Feb 2027Cardioprotective and Mental Health Benefits of the MIND Diet Combined With Forest Bathing · Tung Wah College
- Feb 2027Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 · Northwestern University
- Mar 2027Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) · Nantes University Hospital
- Mar 2027Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia · Brigham and Women's Hospital
- Apr 2027A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Who these studies take
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger. 17 (47%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (14%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 14 (39%) | 14 (39%) |
| 18 | 29 (81%) | 29 (81%) |
| 30 | 26 (72%) | 26 (72%) |
| 40 | 27 (75%) | 27 (75%) |
| 50 | 28 (78%) | 28 (78%) |
| 65 | 27 (75%) | 27 (75%) |
| 75 | 22 (61%) | 22 (61%) |
| 85 | 20 (56%) | 20 (56%) |
Across all 249 studies, recruiting or not: 39% stop at 75 or younger and 24% at 65; 30% take children; 1% are for women only and 1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Hyperlipoproteinemia Type II studies take
Of 33 phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 24 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 24 mo18–34 · 33 studies | 23 mo18–34 · 29 studies | — |
| Interventional, no phase | 29 mo12–41 · 37 studies | — | 37 mo12–51 · 35 studies |
| Observational | 76 mo23–… · 32 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered3
- Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3Nov 5, 2026NCT07919353
- Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)Nov 3, 2026NCT07912281
- EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Oct 26, 2026NCT07894887
Studies
Recruiting first, then most recently updated. Showing 50 of 249. Browse all 249 → or search them.
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)RecruitingNCT07058077Phase 2/320 countries
- Lipid Transport Disorder Italian Genetic Record (LIPIGEN)RecruitingNCT063624731 country
- Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3Not yet recruitingNCT07919353Not applicable1 country
- An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial HypercholesterolemiaNot yet recruitingNCT07606118
- EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Not yet recruitingNCT07894887Phase 1/21 country
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaRecruitingNCT07473843Phase 33 countries
- Phase 1b Study of VERVE-201 in Patients With Refractory HyperlipidemiaRecruitingNCT06451770Phase 16 countries
- The ORIGIN-FH StudyRecruitingNCT07470723Not applicable1 country
- Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaRecruitingNCT07223658Phase 1/25 countries
- Computerized Decision Support for Identification and Management of Familial HypercholesterolemiaRecruitingNCT06743659Not applicable1 country
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesRecruitingNCT05682378Phase 326 countries
- Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCPNot yet recruitingNCT07653555Not applicable1 country
- The Spanish Familial Hypercholesterolaemia Cohort StudyRecruitingNCT026935481 country
- A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery DiseaseRecruitingNCT06164730Phase 16 countries
- Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial HypercholesterolemiaNot yet recruitingNCT07775339Phase 35 countries
- 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)RecruitingNCT04941599Phase 21 country
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingNCT06597006Phase 311 countries
- A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaRecruitingNCT07695597Phase 21 country
- A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruitingNCT075437311 country
- A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)RecruitingNCT07465263Phase 31 country
- Child-Parent Familial Hypercholesterolemia ScreeningRecruitingNCT045299671 country
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingNCT06597019Phase 323 countries
- National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter RegistryRecruitingNCT065461371 country
- Comparing Direct vs Indirect Methods for Cascade ScreeningRecruitingNCT05348564Not applicable1 country
- Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular DiseaseEnrolling by invitationNCT061123272 countries
- A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaRecruitingNCT07421297Phase 31 country
- Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)RecruitingNCT06960902Not applicable1 country
- Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary EfficacyNot yet recruitingNCT07353398Early Phase 11 country
- Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty AcidsRecruitingNCT04485871Not applicable1 country
- QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)Not yet recruitingNCT07450378Phase 3
- QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)Not yet recruitingNCT07441317Phase 3
- EAS Familial Hypercholesterolaemia Studies CollaborationRecruitingNCT042726971 country
- QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed DyslipidemiaNot yet recruitingNCT07444086Phase 3
- Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.RecruitingNCT05614219Not applicable1 country
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyNot yet recruitingNCT07421284Phase 31 country
- Screening for Familial Hypercholesterolemia in ChildrenRecruitingNCT06555120Not applicable1 country
- Penn Family Screening for Familial HypercholesterolemiaEnrolling by invitationNCT05750667Not applicable1 country
- Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)Enrolling by invitationNCT05284513Not applicable1 country
- Cardiovascular Risk in Children With Chronic Conditions StudyRecruitingNCT070869891 country
- Atlantic Lipid Lowering Treatment Optimization ProgramRecruitingNCT06439654Not applicable1 country
- Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RecruitingNCT06458010Early Phase 11 country
- Early Detection of Familial Hypercholesterolemia in ChildrenRecruitingNCT043708991 country
- Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in EmiratisRecruitingNCT06535542Not applicable1 country
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingNCT06568471Phase 31 country
- Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL CholesterolNot yet recruitingNCT06750341Phase 2
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationNCT04798430Phase 36 countries
- PMMHRI - Familial Hypercholesterolemia RegistryRecruitingNCT065716301 country
- Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RecruitingNCT06461702Early Phase 11 country
- Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia PatientsNot yet recruitingNCT06293729Early Phase 1
- Cardioprotective and Mental Health Benefits of the MIND Diet Combined With Forest BathingEnrolling by invitationNCT06222632Not applicable1 country